DNLI

$24.82-$0.45 (-1.78%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$4.0B

160M shares

52-week range

$12.58 – $27.30

83% from low

Sector

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Exchange

NASDAQ

Change$-26.98

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$35M	+1299.4%	$-2.41	$-2.74–$-1.55	—	14
2027	$106M	+204.0%	$-2.44	$-2.84–$-2.04	—	15
2028	$267M	+150.9%	$-1.84	$-3.16–$0.27	—	14
2029	$439M	+64.7%	$-0.98	$-3.53–$-0.04	—	7

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Denali Therapeutics Inc. Common Stock

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

www.denalitherapeutics.com

Employees: 507
IPO / List date: Dec 8, 2017
HQ: SOUTH SAN FRANCISCO, CA

Held by traders on TradeandTell

No one on the platform currently holds DNLI.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-12-31	10,700	$176.7K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded DNLI yet.

$DNLI chatter on StockTwits

Estimize@Estimize5h
Wall St is expecting -0.39 EPS for $DNLI Q3 [Reporting 11/11 AMC] http://www.estimize.com/intro/dnli?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
Levi Davidson@GoAt2OGBullish11h
$DNLI started off with 750 commons here; let’s see how this moves along
View on StockTwits ↗
Levi Davidson@GoAt2OGBullish14h
$DNLI looking to start a position here; fishing 🎣
View on StockTwits ↗
PRISM MarketView@prismmarketview3d
(NASDAQ: $DNLI ) Denali Therapeutics believes improving how medicines are delivered across the blood-brain barrier could unlock better outcomes in Alzheimer's disease. With two clinical-stage Alzheimer's programs now advancing and initial human data expected in 2027, investors are increasingly watching whether Denali's proprietary TransportVehicle™ platform can translate promising science into clinical results. https://prismmarketview.com/denali-bets-better-brain-distribution-could-shape-the-next-generation-of-alzheimers-therapies/
View on StockTwits ↗
Swingstocktraders@stockpicker63Bullish4d
$DNLI — TA + AI Analysis (Short-Term Bullish Setup)
View on StockTwits ↗
D G@dgbioBullishAug 7
$DNLI Orphan Drug designation just received for the FTD-GRN program.
View on StockTwits ↗
D G@dgbioBullishAug 7
$DNLI Guidance for Q3 revenue is 10-12 million, 2x consensus of 5.5 million.
View on StockTwits ↗
Nicholas@JFDIAug 6
$DNLI Weekly base
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderAug 6
https://www.marketbeat.com/earnings/reports/2026-8-6-denali-therapeutics-inc-stock/ $DNLI Denali Therapeutics Earnings Transcript
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 6
$DNLI Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.68 up 5.56% YoY • Reported revenue of $3.6M
View on StockTwits ↗
Joe@Jh900Aug 6
$DNLI earnings .. what are we saying ?
View on StockTwits ↗
Tad Sullivan@TadstonkBullishAug 3
$DNLI Received Orphan designation for FTD/progranulan
View on StockTwits ↗
Merlintrader Trading Pub@MerlintraderJul 25
$RCKT $DNLI $XBI $IBB
View on StockTwits ↗
David Shapiro@B2iDigitalJul 24
eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
View on StockTwits ↗
Northridge G-101 SPM Company@G101SPMJul 24
#SHOWTIME International AIDS Conference (July 27-31) Scheduled to appear: $MRK BTIG Biotechnology Conference (July 27) Scheduled to appear: $DNLI, $MLTX, $PCVX
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.51	$-0.68	-32.5%
2026-05-07	$-0.73	$-0.69	+5.5%
2026-02-26	$-0.75	$-0.73	+2.7%
2025-11-06	$-0.76	$-0.74	+2.6%
2025-08-11	$-0.74	$-0.72	+2.7%
2025-05-06	$-0.71	$-0.78	-9.9%
2025-02-27	$-0.75	$-0.67	+10.7%
2024-11-06	$-0.60	$-0.63	-5.0%

Symbol	Price	Today	Mkt cap	P/E
DNLIDenali Therapeutics Inc.	$24.82	-1.78%	$3.9B	—
AGIOAgios Pharmaceuticals, Inc.	$33.47	-2.16%	$2.0B	—
BEAMBeam Therapeutics Inc.	$26.51	-0.75%	$2.7B	—
COGTCogent Biosciences, Inc.	$37.31	-4.28%	$6.4B	—
ETNB89bio, Inc.	$14.84	+0.00%	$2.2B	—
GLPGGalapagos N.V.	$27.98	+1.71%	$1.8B	—
IBRXImmunityBio, Inc.	$7.65	-1.16%	$8.0B	—

DNLI

Analyst estimates (consensus)

Earnings surprises

Denali Therapeutics Inc. Common Stock

Held by traders on TradeandTell

Super investors & insiders

Recent trades on TradeandTell

$DNLI chatter on StockTwits

$DNLI chatter on StockTwits

Analyst estimates (consensus)

Earnings surprises

DCF fair valuemodel estimate

Peer comparison